Project ECHO® COVID-19 Global Series

COVID-19 GLOBAL CONVERSATIONS
Antibody Treatment

Monoclonal antibody (mAb) treatment has been authorized by the US FDA for emergency use application for COVID-19 patients. This session provides an overview of the results of recent clinical trials, updates on treatment efficacy and lessons learned from clinical administration in outpatient and long-term care settings.

Featured Panelist

Janet Woodcock, MD,
Director of the Center for Drug Evaluation and Research, Food and Drug Administration

This session addresses:

- Results of clinical trials of mAb treatment
- Evidence-based lessons learned from clinical administration of treatment
- Specific considerations for application in long-term care facilities

Additional Panelists:

- Mark Gerdes, RPh, Director, Avera Long-Term Care Pharmacy
- Anna Meyer, PharmD, Clinical Coordinator, Avera Long-Term Care Pharmacy
- Alisha Parada, MD, FACP, Division Chief, General Medicine and Geriatrics, University of New Mexico, Health Sciences Center
- Karl Steinberg, MD, Chief Medical Officer, Mariner Health Care Central

Facilitated by:

- Sanjeev Arora, MD, Director, Project ECHO
- Matthew Bouchonville, MD, Associate Director, ECHO Institute

Thursday, December 10, 2020

12:30 – 2:00 pm MST; 2:30 – 4:00 pm EST; 930 – 2100 UTC Time Zone Converter

This activity has been approved for AMA PRA Category 1 Credits™ Simultaneous French and Spanish interpretation available.

REGISTER HERE

ECHO COVID-19 Global Conversations Webpage | ECHOCOVID19GlobalSeries@salud.unm.edu

This series of teleECHO sessions addresses up-to-date concerns, information on evidence-based best practices and updates on the transmission, spread, and clinical management of COVID-19.
This supplemental session is an optional addition to any ECHO curriculum or program.

This session has been produced in collaboration with:

U.S. Department of Health and Human Services

amda The Society for Post-Acute and Long-Term Care Medicine

This series has been created with the generous philanthropic support of the Bristol Myers Squibb Foundation

Bristol Myers Squibb™ Foundation